Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
CNS Spectr ; 21(1): 60-9, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26726766

ABSTRACT

OBJECTIVES: To analyze antipsychotic prescribing patterns in a UK high security hospital (HSH) that treats seriously violent men with either schizophrenia or personality disorder and examine how different groups consented to treatment and prescribing for metabolic conditions. We hypothesized that there would be high prevalence of antipsychotic polypharmacy, and high-dose antipsychotic and clozapine prescribing. BACKGROUND: HSHs treat seriously violent, mentally disordered offenders, and the extant literature on prescribing patterns in forensic settings is sparse. METHODS: Prescribing and clinical data on all 189 patients in a UK HSH were collected from the hospital's databases. Data were analyzed using SPSS. RESULTS: The population was split into the following groups: schizophrenia spectrum disorder (SSD-only), personality disorder (PD-only), and comorbid schizophrenia spectrum disorder and PD. The majority (93.7%) of all patients were prescribed at least one antipsychotic, and (27.5%) were on clozapine. Polypharmacy was prevalent in 22.2% and high-dose antipsychotic in 27.5%. Patients on clozapine were more likely to be prescribed antidiabetic, statins, or antihypertensive medication. Patients in the PD-only group were more likely to be deemed to have the capacity to consent to treatment and be prescribed clozapine in contrast to the SSD-only group. CONCLUSIONS: Rates of clozapine and high-dose antipsychotic prescribing were higher than in other psychiatric settings, while polypharmacy prescribing rates were lower. Higher clozapine prescribing rates may be a function of a treatment-resistant and aggressive population. A higher proportion of PD-only patients consented to treatment and received clozapine compared with in-house SSD-only as well as other psychiatric settings. Implications of the findings are discussed.


Subject(s)
Antipsychotic Agents/therapeutic use , Clozapine/therapeutic use , Personality Disorders/drug therapy , Psychotic Disorders/drug therapy , Schizophrenia/drug therapy , Violence , Adult , Antihypertensive Agents/therapeutic use , Criminals , Diabetes Mellitus/drug therapy , Diabetes Mellitus/epidemiology , Dyslipidemias/drug therapy , Dyslipidemias/epidemiology , Hospitals, Psychiatric , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hypertension/drug therapy , Hypertension/epidemiology , Hypoglycemic Agents/therapeutic use , Informed Consent , Male , Middle Aged , Personality Disorders/epidemiology , Polypharmacy , Practice Patterns, Physicians' , Psychotic Disorders/epidemiology , Schizophrenia/epidemiology , United Kingdom
SELECTION OF CITATIONS
SEARCH DETAIL
...